HOME >> MEDICINE >> NEWS
Further Evidence On The Effect Of The UK Cervical Screening Programme

(Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model)

In this week's BMJ a paper written by Dr Peter Sasieni and Joanna Adams from the Imperial Cancer Research Fund supports recent findings of a beneficial effect of the national cervical screening programme. The authors say that before the relaunch of the programme in 1988 screening had a minimal effect on mortality, but since its relaunch screening appears to have reduced cervical cancer mortality by over 60 per cent in those aged under 55 years (up until 1997). They estimate that 1300 lives were saved in 1997 by screening in previous years.

Contact:

Dr Peter Sasieni, Senior Scientist, Department of Mathematics, Statistics and Epidemiology, Imperial Cancer Research Fund, London comms@icrf.icnet.uk Further Evidence on the Effect of the National Cervical Screening Programme In this week's BMJ, researchers support recent findings of a beneficial effect of the national cervical screening programme. The authors say that since its relaunch screening appears to have reduced cervical cancer mortality by over 60 per cent in those aged under 55 years.


'"/>

Contact: Jill Shepherd
jshepherd@bma.org.uk
44-171-383-6529
BMJ-British Medical Journal
7-May-1999


Page: 1

Related medicine news :

1. Further evidence reveals the association between periodontal disease and coronary artery disease
2. Further evidence showing treatment benefits of beta interferon for MS
3. Further studies comparing rehydration therapies would waste resources, say researchers
4. Further evidence for effectiveness of nevirapine in reducing mother-to-child HIV-1 transmission
5. Further evidence that HRT does not protect against cardiovascular disease
6. Further evidence linking suicide risk to family history (p 1126)
7. Further evidence of increase in allergic disease in western countries
8. Holding Policy Is Cost-Effective Way To Further Protect Blood Plasma Supply From HIV And Other Infections
9. Jefferson Physician Warns Further Study Of DHEAs Safety Needed
10. Evidence indicates cancer patients unable to intentionally postpone death for significant events
11. Not guilty! Evidence exonerates 328, but many still falsely imprisoned

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology:
Cached News: